TROKENDI Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Trokendi, and what generic alternatives are available?
Trokendi is a drug marketed by Supernus Pharms and is included in one NDA. There are ten patents protecting this drug.
The generic ingredient in TROKENDI is topiramate. There are twenty-six drug master file entries for this compound. Fifty suppliers are listed for this compound. Additional details are available on the topiramate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Trokendi
A generic version of TROKENDI was approved as topiramate by ACCORD HLTHCARE on March 27th, 2009.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for TROKENDI?
- What are the global sales for TROKENDI?
- What is Average Wholesale Price for TROKENDI?
Summary for TROKENDI
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Prices: | Drug price information for TROKENDI |
| Drug Sales Revenues: | Drug sales revenues for TROKENDI |
| DailyMed Link: | TROKENDI at DailyMed |
US Patents and Regulatory Information for TROKENDI
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Supernus Pharms | TROKENDI XR | topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 201635-004 | Aug 16, 2013 | AB1 | RX | Yes | Yes | 9,555,004 | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Supernus Pharms | TROKENDI XR | topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 201635-003 | Aug 16, 2013 | AB1 | RX | Yes | No | 9,622,983 | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Supernus Pharms | TROKENDI XR | topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 201635-003 | Aug 16, 2013 | AB1 | RX | Yes | No | 8,298,580 | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Supernus Pharms | TROKENDI XR | topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 201635-003 | Aug 16, 2013 | AB1 | RX | Yes | No | 8,889,191 | ⤷ Start Trial | ⤷ Start Trial | |||
| Supernus Pharms | TROKENDI XR | topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 201635-004 | Aug 16, 2013 | AB1 | RX | Yes | Yes | 9,622,983 | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Supernus Pharms | TROKENDI XR | topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 201635-002 | Aug 16, 2013 | AB1 | RX | Yes | No | 8,298,580 | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Supernus Pharms | TROKENDI XR | topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 201635-002 | Aug 16, 2013 | AB1 | RX | Yes | No | 8,992,989 | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
